Epigral Ltd reported a 38% drop in quarterly profit to ₹99.74 crore, largely due to a shift in tax rates. Despite lower profits, the company announced a ₹600 crore investment to enter the epoxy resin and formulations market. This expansion aims to boost its specialty chemical portfolio, though shareholders should track the execution timeline leading up to 2028.
Detailed Coverage
Epigral Ltd, formerly known as Meghmani Finechem, announced its financial results for the first quarter of the 2026-27 fiscal year, showing a consolidated net profit of ₹99.74 crore. This represents a 38% decline compared to the ₹160.79 crore profit recorded in the same quarter last year. The company clarified that this decrease is largely technical, resulting from a shift to a new corporate tax rate of 25.17% beginning in the April-June 2026 period. This transition required an adjustment that reduced its deferred tax liability by ₹81 crore, which affected the reported bottom-line profit figure.
While profits faced pressure, the company’s revenue operations showed growth, with total income reaching ₹709.46 crore for the quarter. To sustain this momentum, the company’s board has approved a major capital spending plan of ₹600 crore. This investment is directed toward establishing new manufacturing facilities in Gujarat, marking the company’s formal entry into the epoxy resin and formulations business.
Strategic Expansion into Epoxy Resins
The upcoming plants are expected to have an annual production capacity of 1.25 lakh tonnes. By moving into epoxy resins, Epigral is looking to strengthen its position in high-performance materials used in industrial coatings, automotive parts, and windmill blades. Commercial production from these new units is currently targeted to begin in the second half of the 2028 fiscal year. This project represents a forward integration strategy, as the company aims to use its existing chemical value chains to create higher-value products.
Multi-Purpose Plant for Intermediates
In addition to the epoxy project, Epigral is constructing a multi-purpose plant designed to process downstream products from its existing epichlorohydrin and chlorotoluenes chains. This facility is intended to meet the domestic demand for pharmaceutical and agrochemical intermediates, as well as chemicals used in water treatment. These sectors are often sensitive to regulatory changes and domestic import trends, which may influence demand for the company’s intermediate products.
Investors should note that the chemical industry in India currently faces challenges related to global pricing volatility and the need for consistent volume growth in specialty segments. As Epigral moves forward with this ₹600 crore expansion, the key monitorables will be the project’s execution timeline, the ability to maintain profit margins amid new capacity ramp-ups, and the impact of these capital outlays on the company's debt position. The long gestation period until the 2028 commercial launch means shareholders will need to track quarterly updates on construction progress and raw material cost trends.